We also present a novel therapeutic approach using CD133 + Exo not only to improve neurological and cognitive outcome post-stroke in T2DM mice but also to reduce the progression of NAFLD/NASH after stroke. Here, PROM1 is linked to metabolic dysfunction-associated steatotic liver disease.